Acadia submits Rett Syndrome New Drug Application to the FDA
Posted: 19 July 2022 Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) is pleased to report that its US partner Acadia Pharmaceuticals (Nasdaq: ACAD) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for…
ANDHealth extends partnership with Therapeutic Goods Administration to accelerate digital health regulatory adoption and commercialisation
Posted: July 18 2022 ANDHealth, Australia’s leading digital health commercialisation organisation, has announced the extension of its partnership with the Therapeutic Goods Administration (TGA) to support Australia’s fast-growing digital health sector. The extended partnership will see TGA fund…
Advertising of Therapeutic Goods in Australia – Are your advertising campaigns compliant? – Stephens Lawyers & Consultants
Posted: 23 June 2022 Advertising compliance for therapeutic goods in Australia is complex, requiring one to remain up-to-date on a number of different advertising laws which are administered by different regulators. This article provides a timely reminder that as…
First harvest at medicinal cannabis facility near Mildura in Victoria’s north-west
Posted: 16 June 2022 Key points: The first crop has been harvested from a medicinal cannabis facility built in a former fruit juice factory near Mildura Cann Group received approval to cultivate the crop at the $115 million…
Record 65,000 flu cases in May as experts warn 2022 flu resurgence redefines what it means to be ‘flu ready’
Posted: 14 June 2022 Infectious disease experts gathered at the BioMelbourne Network BioForum today to share concerns regarding influenza (flu) preparedness, emerging public health challenges and vaccine innovation.1 According to data captured by the National Notifiable Disease…
Immutep’s TACTI-002 trial meets primary endpoint in lung cancer
Posted: 6 June 2022 Immutep reports positive Overall Response Rate in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients…
Committee for Melbourne – Welcome to our new CEO, Mark Melvin!
Posted: 2 June 2022. I would firstly like to say thank you to our members, stakeholders and secretariat for such a warm welcome. It is in an honour and a privilege to lead the Committee for Melbourne into…
Amplia Therapeutics (ASX:ATX) shows efficacy in model of lung fibrosis
Date posted: 2 June 2022 Amplia has released new data showing that in a head-to-head preclinical comparison, using a mouse model of idiopathic pulmonary fibrosis (IPF), AMP945 showed comparable efficacy to the current standard of care. The current…
Ed Husic is Australia’s new Industry & Science Minister
Posted: 31 May 2022 Written by – Denham Sadler National Affairs Editor InnovationAus.com Long-time tech and innovation advocate Ed Husic will be Australia’s new Industry Minister after he retained his spot in the new Labor government’s Cabinet, with Clare…
Avatar Brokers Celebrates 20 Years
Posted: 30 May 2022 Avatar Brokers are proud to announce a significant milestone in the history of our company, with this month marking our 20th anniversary. Founded on May 29, 2002, Avatar Brokers began its operations after establishing…
Deadly partnership to bolster First Nations representation in medical research
Posted: 27 May 2022 WEHI has partnered with leading Indigenous not-for-profit, DeadlyScience, to foster the next generation of Aboriginal and Torres Strait Islander scientists, in the first partnership of its kind. At a glance WEHI partners with DeadlyScience to pave the…
Burnet Institute partners with Moderna to develop novel mRNA vaccines
Posted: 26 May 2022 Media Release: 18 May 2022 Burnet Institute is to partner with world-leading mRNA vaccine manufacturer Moderna, through their cutting-edge mRNA Access program, to develop novel mRNA vaccines for a range of emerging and neglected infectious…
